EUCTR2012-003349-13-IT进行中（未招募）不适用
Study NOG112264, a Phase II Study of Ozanezumab(GSK1223249) versus Placebo in the Treatment of AmyotrophicLateral Sclerosis - Ozanezumab Phase II study in patients with ALS
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 294
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients with diagnosis of familial or sporadic ALS, defined as meeting the possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS according to the revised World Federation of Neurology El Escorial criteria [Rix Brooks, 2000].2. Onset of muscle weakness no more than 30 months before screening visit.3. SVC of at least 65% predicted for gender, age, ethnicity and height at Screening.4. If on riluzole, the dose must have been stable for at least 28 days prior to Baseline visit.5. Age 18 – 80 years inclusive.6. Female subjects may participate if they are of non-child-bearing potential or if they are of child-bearing potential and agree to satisfy one of the requirements for contraception listed in Appendix 4 (Section 11.4)during the study and 4 months after the last dose to avoid pregnancy. Women of childbearing potential must have a negative pregnancy test and be non-lactating.7. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT)= 2x upper limit of normal (ULN); alkaline phosphatase and bilirubin = 1.5xULN. 8. QTc (both QTcB and QTcF) <450 milliseconds (msec) or <480 msec for subjects with Bundle Branch Block at Screening and Baseline (average from triplicate ECGs).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 279
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •1. Patients with other neuromuscular disorders (including a history of polio), which in the opinion of the investigator could have contributed to the muscular atrophy or weakness caused by ALS or could have any other effect on the study efficacy or safety assessments that in the opinion of the investigator would impact participation in the study. 2. Patients with primary lateral sclerosis, monomelic ALS, ALS Parkinsonism dementia complex. 3. Patients requiring non-invasive or mechanical ventilation (noninvasive ventilation for sleep apnoea is allowed subject to discussion with Medical Monitor). 4. Patients on diaphragmatic pacing. 5. Presence of any of the following clinical conditions: a. Drug abuse or alcoholism (according to Diagnostic and Statistical Manual of Mental Disorders –Fourth Edition [DSM-IV] criteria). b. Uncontrolled hypertension despite optimal antihypertensive treatment; unstable cardiovascular, pulmonary, renal, endocrine or hematologic condition; current malignancy. c. Active major infectious disease e.g. systemic infections with visceral involvement (pneumonia, pyelonephritis, endocarditis) and/or septicaemia. d. Unstable psychiatric illness, such as psychosis or untreated major depression, within 90 days of the Screening visit. 6. Subjects, who in the investigator's judgement, pose a significant suicide risk. 7. Current or chronic history of liver disease, known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones), positive Hepatitis B surface antigen or Hepatitis C antibody test. 8. Subjects who have participated in a clinical trial involving receipt of a biopharmaceutical product (recombinant proteins, monoclonal antibodies, blood products, sera, allergens, and gene and cell therapy products) within 6 months prior to the first dosing day. 9. Patients who have received any type of vaccination within 2 weeks prior to study drug administration. 10. Chronic (>3 months) use of systemic immunosuppressants including systemic steroids. 11. Exposure to non-biological experimental agents (including investigational products and marketed medications used off-label) 1 month or 5 half-lives prior to Baseline visit (whichever is longer). 12. History of sensitivity to ozanezumab, or components thereof, or a history of other allergies that, in the opinion of the investigator, contraindicates participation in the study.
研究者
相似试验
进行中（未招募）
不适用
A Study of Ozanezumab (GSK1223249) versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosis (ALS)MedDRA version: 15.0Level: PTClassification code 10002026Term: Amyotrophic lateral sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2012-003349-13-BEGlaxoSmithKline Research and Development Limited294
进行中（未招募）
不适用
A Study of Ozanezumab (GSK1223249) versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosis (ALS)MedDRA version: 14.1Level: PTClassification code 10002026Term: Amyotrophic lateral sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2012-003349-13-NLGlaxoSmithKline Research and Development Limited294
进行中（未招募）
不适用
A Study of Ozanezumab (GSK1223249) versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis (ALS)EUCTR2012-003349-13-DEGlaxoSmithKline Research and Development Limited294
已完成
2 期
Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) versus Placebo in the Treatment of Amyotrophic Lateral SclerosisALSAmyotrophic Lateral Sclerosis10029317NL-OMON37243GlaxoSmithKline BV28
进行中（未招募）
1 期
A Study of Ozanezumab (GSK1223249) versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosis (ALS)MedDRA version: 14.1 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disordersEUCTR2012-003349-13-FRGlaxoSmithKline Research and Development Limited303